The trajectory of Sildenafil presents a challenging picture for investors. While the initial introduction generated substantial gains, the lapse of its patent opened the avenue to off-brand versions, dramatically https://webcastlist.com/story23136413/the-copyright-and-big-pharma-a-risky-investment